146 related articles for article (PubMed ID: 17507326)
1. Long-term control of viral residual replication under maintenance therapy with Trizivir after a quadruple induction regimen in HIV-1-infected adults (Suburbs trial).
de Truchis P; Mathez D; Force G; Rouveix E; Khuong MA; Chemlal K; Thiaux C; Leibowitch J
HIV Clin Trials; 2007; 8(2):102-4. PubMed ID: 17507326
[No Abstract] [Full Text] [Related]
2. Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.
Ruane PJ; Parenti DM; Margolis DM; Shepp DH; Babinchak TJ; Van Kempen AS; Kauf TL; Danehower SA; Yau L; Hessenthaler SM; Goodwin D; Hernandez JE;
HIV Clin Trials; 2003; 4(4):231-43. PubMed ID: 12916008
[TBL] [Abstract][Full Text] [Related]
3. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
Ruane P; Lang J; DeJesus E; Berger DS; Dretler R; Rodriguez A; Ward DJ; Lim ML; Liao Q; Reddy S; Clair MS; Vila T; Shaefer MS
HIV Clin Trials; 2006; 7(5):229-36. PubMed ID: 17162316
[TBL] [Abstract][Full Text] [Related]
4. Anti-HIV agents. Trizivir--three drugs in one pill.
TreatmentUpdate; 2000 Feb; 12(1):1-2. PubMed ID: 12125625
[No Abstract] [Full Text] [Related]
5. Abacavir sulfate, lamivudine, and zidovudine (Trizivir).
Porche D
J Assoc Nurses AIDS Care; 2001; 12(6):88-90. PubMed ID: 11723917
[TBL] [Abstract][Full Text] [Related]
6. Quadruple-drug induction HAART in advanced HIV infection.
Maggiolo F; Ripamonti D; Callegaro A; Gregis G; Quinzan G; Suter F
HIV Clin Trials; 2005; 6(1):1-4. PubMed ID: 15765306
[TBL] [Abstract][Full Text] [Related]
7. Triple nuke therapy--results after one year.
TreatmentUpdate; 2001; 12(10):3-4. PubMed ID: 11570063
[No Abstract] [Full Text] [Related]
8. Open-label phase II trial of amprenavir, abacavir, and fixed-dose zidovudine/lamivudine in newly and chronically HIV-1--infected patients.
Kost RG; Hurley A; Zhang L; Vesanen M; Talal A; Furlan S; Caldwell P; Johnson J; Smiley L; Ho D; Markowitz M
J Acquir Immune Defic Syndr; 2001 Apr; 26(4):332-9. PubMed ID: 11317074
[TBL] [Abstract][Full Text] [Related]
9. AACTG A5095, Trizivir, and the role of all-nucleoside regimens: an editorial.
Gallant JE
Hopkins HIV Rep; 2003 Jul; 15(4):1-2. PubMed ID: 14696559
[No Abstract] [Full Text] [Related]
10. Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen.
Stürmer M; Dauer B; Moesch M; Haberl A; Mueller A; Locher L; Knecht G; Hanke N; Doerr HW; Staszewski S
Antivir Ther; 2007; 12(1):25-30. PubMed ID: 17503744
[TBL] [Abstract][Full Text] [Related]
11. Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adults.
Mallolas J; Pich J; Peñaranda M; Domingo P; Knobel H; Pedrol E; Gutiérrez F; Barrufet P; Peraire J; Asenjo MA; Vidal F; Gatell JM
AIDS; 2008 Jan; 22(3):377-84. PubMed ID: 18195564
[TBL] [Abstract][Full Text] [Related]
12. [Compact therapy with 2 tablets daily. Initial triple combination tablet simplifies HIV therapy].
MMW Fortschr Med; 2001 Apr; 143 Suppl 1():50-1. PubMed ID: 11373780
[No Abstract] [Full Text] [Related]
13. We want our Trizivir!
Vázquez E
Posit Aware; 2003; 14(5):25-6. PubMed ID: 14679938
[No Abstract] [Full Text] [Related]
14. Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART: the Trizal study.
Lafeuillade A; Clumeck N; Mallolas J; Jaeger H; Livrozet JM; Ferreira Mdo S; Johnson M; Cheret A; Antoun Z;
HIV Clin Trials; 2003; 4(1):37-43. PubMed ID: 12577195
[TBL] [Abstract][Full Text] [Related]
15. [Results of the TRIZAL Study. Therapy change with positive concomitant effect].
MMW Fortschr Med; 2001 Apr; 143 Suppl 1():51-2. PubMed ID: 11373781
[No Abstract] [Full Text] [Related]
16. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W;
JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744
[TBL] [Abstract][Full Text] [Related]
17. Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment.
Rozenbaum W; Katlama C; Massip P; Bentata M; Zucman D; Delfraissy JF; Trepo C; David F; Lanier ER; Vavro C; Mamet JP
Antivir Ther; 2001 Jun; 6(2):135-42. PubMed ID: 11491418
[TBL] [Abstract][Full Text] [Related]
18. [First HIV triple therapy with one tablet].
Dtsch Med Wochenschr; 2000 Feb; 125(8):A22. PubMed ID: 10723466
[No Abstract] [Full Text] [Related]
19. Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naïve subjects: a 48-week pilot study.
Elion R; Cohen C; DeJesus E; Redfield R; Gathe J; Hsu R; Yau L; Ross L; Ha B; Lanier RE; Scott T;
HIV Clin Trials; 2006; 7(6):324-33. PubMed ID: 17208898
[TBL] [Abstract][Full Text] [Related]
20. Anti-HIV agents. Abacavir--as good as AZT?
TreatmentUpdate; 2003 Oct; 15(6):3-4. PubMed ID: 17216861
[No Abstract] [Full Text] [Related]
[Next] [New Search]
